-
公开(公告)号：US08409564B2
公开(公告)日：2013-04-02
申请号：US10969011
申请日：2004-10-21
IPC分类号： A61K41/00 , C07D311/82 , C12N13/00
CPC分类号： A61K41/0009 , A61K41/0057 , C07D311/82 , C12N5/0087
摘要： The present invention relates to the use of the photoactivable derivatives for the photodynamic treatment for the selective destruction and/or inactivation of immunologically reactive cells without affecting the normal cells and without causing systemic toxicity for the patient, wherein appropriate intracellular levels of said derivatives are achieved and irradiation of a suitable wavelength and intensity is applied.
摘要翻译： 本发明涉及可光活化衍生物用于光动力学治疗用于免疫反应性细胞的选择性破坏和/或灭活而不影响正常细胞并且不对患者造成全身毒性的用途，其中实现所述衍生物的适当的细胞内水平 并施加合适的波长和强度的照射。
-
2.发明授权Mutated HOXB4 proteins with improved stability, and methods of use thereof 有权具有改善的稳定性的突变的HOXB4蛋白及其使用方法公开(公告)号：US08039436B2
公开(公告)日：2011-10-18
申请号：US12129919
申请日：2008-05-30
CPC分类号： C07K14/47 , A61K38/00 , G01N33/6872
摘要： A polypeptide, the amino acid sequence of which comprises a sequence as set forth in SEQ ID NO:2, including at least one mutation within the degron domain of the polypeptide encompassed between positions 1 and 35 of the sequence, wherein said at least one mutation reduces the susceptibility of the polypeptide to ubiquitin-proteasome degradation.
摘要翻译： 一种多肽，其氨基酸序列包含SEQ ID NO：2所示的序列，包括在序列的第1和35位之间包含的多肽的退链结构域内的至少一个突变，其中所述至少一个突变 降低多肽对泛素 - 蛋白酶体降解的敏感性。
-
3.发明授权Use of ligands specific to major histocompatibility complex-class I antigens for diagnosing endometriosis 失效使用特异于主要组织相容性复合体I类抗原的配体来诊断子宫内膜异位症公开(公告)号：US06376201B2
公开(公告)日：2002-04-23
申请号：US09260305
申请日：1999-03-02
IPC分类号： C12Q168
CPC分类号： G01N33/689 , G01N33/56977 , G01N33/6893 , G01N2800/364 , Y10S435/96 , Y10S435/975
摘要： It is an object of the present invention to provide the clinicians with a new application for ligands specific to MHC-class I antigens, especially HLA-ABC antigens, this new application residing in the detection and diagnosis of endometriosis. It is also an object of the present invention to provide a method and a test kit for diagnosing endometriosis, preferably by immunohistochemistry, using a monoclonal anti- HLA-ABC antibody as a preferred ligand or diagnostic reagent. This new method is non-invasive and is more reliable as a screening test than the conventionally used laparoscopy. When the endometrium of a woman tests negatively with the claimed method, it prevents the use of laparoscopy which is an invasive method for detecting endometriosis. This method can be practised on a specimen obtained from the endometrium of a patient and does not require a specimen sampled directly from the endometriotic foci.
摘要翻译： 本发明的一个目的是为临床医生提供对MHC-I类抗原，特别是HLA-ABC抗原特异性的配体的新应用，该新的应用位于子宫内膜异位症的检测和诊断中。 本发明的另一个目的是提供一种用于诊断子宫内膜异位症的方法和试剂盒，优选通过免疫组织化学，使用单克隆抗HLA-ABC抗体作为优选的配体或诊断试剂。 这种新方法是非侵入性的，并且作为筛选试验比常规使用的腹腔镜检查更可靠。 当妇女的子宫内膜对所要求的方法进行负面测试时，它阻止使用腹腔镜检查，这是用于检测子宫内膜异位症的侵入性方法。 该方法可以在从患者的子宫内膜获得的样本上实施，并且不需要直接从子宫内膜异位灶取样。
-
4.发明申请IMMUNOLOGIC COMPOUNDS FOR PREVENTION, PROTECTION, PROPHYLAXIS OR TREATMENT OF IMMUNOLOGICAL DISORDERS, INFECTIONS AND CANCER 审中-公开用于预防，保护，预防或治疗免疫缺陷病毒，感染和癌症的免疫化学物质公开(公告)号：US20120136338A1
公开(公告)日：2012-05-31
申请号：US13366099
申请日：2012-02-03
IPC分类号： A61M5/00 , A61P37/00 , A61P31/00 , A61P35/00 , A61P31/12 , A61P35/02 , A61P31/10 , A61P33/02 , A61P31/18 , A61P31/14 , A61P31/22 , A61K35/12 , A61P33/00
CPC分类号： A61K31/353 , A61K31/365 , A61K35/28 , A61K38/193 , A61K38/2013 , A61K38/21 , A61K39/0008 , A61K39/0011 , A61K41/0019 , A61K41/0057 , A61K2039/5154 , C09B11/24 , Y02A50/414 , A61K2300/00
摘要： The present invention provides for methods of treating a cancer patient. In one methods, cancer cells are harvested from a patient. A therapeutic amount of a rhodamine derivative is then added to the harvested cancer cells. The harvested cells and the rhodamine derivative are then irradiated with a suitable wavelength and intensity for the selective killing of the cancer cells. The irradiated cancer cells are then mixed with antigen presenting cells to form a mixture. The mixture of cancer and antigen presenting cells are then injected into the patient. The present invention also provides for methods of inhibiting or treating an immunological disorder, infection, or a cancer in an individual.
摘要翻译： 本发明提供了治疗癌症患者的方法。 在一种方法中，从患者收获癌细胞。 然后将治疗量的罗丹明衍生物加入到所获得的癌细胞中。 然后用合适的波长和强度照射收获的细胞和罗丹明衍生物，用于选择性杀死癌细胞。 然后将照射的癌细胞与抗原呈递细胞混合以形成混合物。 然后将癌症和抗原呈递细胞的混合物注射到患者体内。 本发明还提供了抑制或治疗个体的免疫学障碍，感染或癌症的方法。
-
5.发明申请MUTATED HOXB4 PROTEINS WITH IMPROVED STABILITY, AND METHODS OF USE THEREOF 有权具有改善稳定性的突变型HOXB4蛋白及其使用方法公开(公告)号：US20080300187A1
公开(公告)日：2008-12-04
申请号：US12129919
申请日：2008-05-30
IPC分类号： A61K38/17 , C07K14/47 , C07K19/00 , C07K16/18 , C07H21/04 , G01N33/68 , C12P21/02 , C12N15/63 , C12N5/10 , C12N5/06
CPC分类号： C07K14/47 , A61K38/00 , G01N33/6872
摘要： A polypeptide, the amino acid sequence of which comprises a sequence as set forth in SEQ ID NO:2, including at least one mutation within the degron domain of the polypeptide encompassed between positions 1 and 35 of the sequence, wherein said at least one mutation reduces the susceptibility of the polypeptide to ubiquitin-proteasome degradation.
摘要翻译： 一种多肽，其氨基酸序列包含SEQ ID NO：2所示的序列，包括在序列的第1和35位之间包含的多肽的退链结构域内的至少一个突变，其中所述至少一个突变 降低多肽对泛素 - 蛋白酶体降解的敏感性。
-
公开(公告)号：US20060088507A1
公开(公告)日：2006-04-27
申请号：US10969011
申请日：2004-10-21
IPC分类号： A61K35/14 , A61K31/365
CPC分类号： A61K41/0009 , A61K41/0057 , C07D311/82 , C12N5/0087
摘要： The present invention relates to the use of the photoactivable derivatives for the photodynamic treatment for the selective destruction and/or inactivation of immunologically reactive cells without affecting the normal cells and without causing systemic toxicity for the patient, wherein appropriate intracellular levels of said derivatives are achieved and irradiation of a suitable wavelength and intensity is applied.
-
7.发明授权Use of ligands specific to major histocompatibility complex-class I antigens for diagnosing endometriosis 失效使用特异于主要组织相容性复合体I类抗原的配体来诊断子宫内膜异位症
公开(公告)号：US5618680A
公开(公告)日：1997-04-08
申请号：US365085
申请日：1994-12-28
IPC分类号： G01N33/569 , G01N33/68 , C12Q1/68 , G01N33/50
CPC分类号： G01N33/689 , G01N33/56977 , G01N33/6893 , G01N2800/364 , Y10S435/806 , Y10S435/96 , Y10S435/975
摘要： It is an object of the present invention to provide the clinicians with a new application for ligands specific to MHC-class I antigens, especially HLA-ABC antigens, this new application residing in the detection and diagnosis of endometriosis. It is also an object of the present invention to provide a method and a test kit for diagnosing endometriosis, preferably by immunohistochemistry, using a monoclonal anti-HLA-ABC antibody as a preferred ligand or diagnostic reagent. This new method is non-invasive and is more reliable as a screening test than the conventionnally used laparoscopy. When the endometrium of a woman tests negatively with the claimed method, it prevents the use of laparoscopy which is an invasive method for detecting endometriosis. This method can be practiced on a specimen obtained from the endometrium of a patient and does not require a specimen sampled directly from the endometriotic foci.
摘要翻译： 本发明的一个目的是为临床医生提供对MHC-I类抗原，特别是HLA-ABC抗原特异性的配体的新应用，该新的应用位于子宫内膜异位症的检测和诊断中。 本发明的另一个目的是提供一种用于诊断子宫内膜异位症的方法和测试试剂盒，优选通过免疫组织化学，使用单克隆抗HLA-ABC抗体作为优选的配体或诊断试剂。 这种新方法是非侵入性的，作为筛选试验比常规使用的腹腔镜更可靠。 当妇女的子宫内膜对所要求的方法进行负面测试时，它阻止使用腹腔镜检查，这是用于检测子宫内膜异位症的侵入性方法。 该方法可以在从患者的子宫内膜获得的样本上实施，并且不需要直接从子宫内膜异位灶取样。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.02 秒)
